Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury

Dapagliflozin, a new type of drug used to treat diabetes mellitus (DM), is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Although some studies showed that SGLT2 inhibition attenuated reactive oxygen generation in diabetic kidney the role of SGLT2 inhibition is unknown. We evaluated whether SLT...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Chang, Yoon-Kyung, Choi, Hyunsu, Jeong, Jin Young, Na, Ki-Ryang, Lee, Kang Wook, Lim, Beom Jin, Choi, Dae Eun
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2016
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4938401/
https://ncbi.nlm.nih.gov/pubmed/27391020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0158810
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items